Ferrante F, Bronzetti E, Ciriaco E, Felici L, Amenta F
Dipartimento di Scienze Cardiovascolari e Respiratoire, Università La Sapienza, Roma, Italy.
J Hypertens. 1992 Jun;10(6):507-12. doi: 10.1097/00004872-199206000-00002.
The present study was designed to investigate the effect of nicardipine administration upon systolic blood pressure (SBP) and cardiac hypertrophy in spontaneously hypertensive rats (SHR).
SBP, heart: and left ventricle: body weight ratios, the cross-sectional area of cardiocytes, and the ultrastructure of the left ventricle were evaluated.
Ten-week old male SHR and age-matched normotensive Wistar-Kyoto rats were studied for 12 weeks. One group of SHR was treated for 12 weeks with a daily oral dose of 1 mg/kg nicardipine and another group with 1 mg/kg hydralazine; Wistar-Kyoto rats were used as a normotensive control group. Light and electron microscope techniques associated with image analysis and morphometry were used.
Nicardipine administration normalized SBP values and significantly reduced the heart: and left ventricle: body weight ratios. Moreover, administration reduced the cross-sectional area of cardiocytes by approximately 38% in subendocardium and by 24% in subepicardium. Hydralazine administration significantly reduced SBP values but had no effect upon heart: or left ventricle: body weight ratios or the cross-sectional area of cardiocytes. Electron microscopy showed that nicardipine treatment was able to reduce the hypertension-dependent changes in cardiac ultrastructure consisting of alternations to intercalated discs and line Z morphology as well as in the decrease of the mitochondria: myofibrils ratio.
The above data indicate that nicardipine administration is able to reduce SBP and to counter the development of structural and ultrastructural changes in cardiac morphology which represent a common complication of arterial hypertension.
本研究旨在探讨尼卡地平给药对自发性高血压大鼠（SHR）收缩压（SBP）和心脏肥大的影响。
评估SBP、心脏与左心室重量比、心肌细胞横截面积以及左心室超微结构。
对10周龄雄性SHR和年龄匹配的正常血压Wistar - Kyoto大鼠进行为期12周的研究。一组SHR每日口服1mg/kg尼卡地平治疗12周，另一组给予1mg/kg肼屈嗪；Wistar - Kyoto大鼠作为正常血压对照组。采用与图像分析和形态测量相关的光镜和电镜技术。
给予尼卡地平可使SBP值正常化，并显著降低心脏与左心室重量比。此外，给药使心内膜下心肌细胞横截面积减少约38%，心外膜下减少24%。给予肼屈嗪可显著降低SBP值，但对心脏或左心室重量比或心肌细胞横截面积无影响。电镜显示，尼卡地平治疗能够减轻高血压相关的心脏超微结构变化，包括闰盘和Z线形态改变以及线粒体与肌原纤维比例降低。
上述数据表明，给予尼卡地平能够降低SBP，并对抗心脏形态结构和超微结构变化的发展，这些变化是动脉高血压的常见并发症。
